10 results about "Surgical resection" patented technology

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

Provided herein are compositions and methods for treating a glioblastoma in a patient after surgical resection, radiation therapy and chemotherapy comprising administering to the patient a therapeutically effective amount of an intravenous liposomal curcumin or curcuminoids to a human subject in need thereof after surgical resection of the glioblastoma a dosing regimen comprising the therapeutically effective amount of the liposomal curcumin or curcuminoids of at least 300 mg / m2 over 8 hours or less, and wherein a treatment cycle is for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consecutive weeks.

The present application relates to the technical field of tumor biology, and specifically discloses a human malignant giant cell tumor of bone cell line and application thereof, the human malignant giant cell tumor of bone cell line is preserved on April 9, 2025, the preservation address is China Center for Type Culture Collection, located in Wuhan University in Wuhan, Hubei Province, and the preservation number is CCTCC NO:C202539.The human malignant giant cell tumor of bone cell line of the present application is from the tumor tissue after surgical resection of a Chinese malignant giant cell tumor of bone patient, and is suitable as cell material for developing malignant giant cell tumor of bone related immunotherapy, diagnosis and drug development.The cell line of the present application contains H3F3A G34W mutation, and has high sensitivity and specificity in the diagnosis of malignant giant cell tumor of bone.This cell line can be used as a tool cell for researching target drugs with H3F3A as a target, provides a cell model for Chinese malignant giant cell tumor of bone research, and provides an experimental platform for mechanism research of malignant giant cell tumor of bone.

A method for marking a lesion is disclosed herein. The disclosed method can assist a surgeon in identifying the location of a nodule or other lesion by marking the nodule or other lesion using a reference marker impregnated with a luminescent material, such as a reference coil impregnated with a fluorescent dye. In some preferred embodiments, the reference coil is placed using a robotic surgical system during a biopsy. In alternative embodiments, a non-robotic peripheral navigation platform may also be effectively used as an aid to surgical resection. The dye marks the location of the nodule or other lesion, allowing it to be visualized and detected by palpation during surgery. Accordingly, the surgeon can target the tissue to be removed with greater accuracy. The disclosed method enables the reference marker to be placed several days prior to surgery.

This invention relates to the fields of bionanotechnology and molecular imaging, disclosing a probe, its preparation method, and its applications. The probe comprises, from the inside out, a near-infrared II (NIR-II) fluorescent core, a gold nanoshell, an MMP-responsive peptide layer, and a pH-sensitive polymer layer. Utilizing the quenching effect of the gold shell on the core fluorescence, the probe remains in a "silent" state in the circulatory system. Its core design lies in the physical shielding effect of the peptide layer, ensuring that the probe must first be unlocked by cleavage by MMP enzymes highly expressed in the tumor, followed by protonation and shedding of the polymer layer under a slightly acidic environment to restore fluorescence. This invention effectively overcomes the non-specific activation of single-response probes in inflammatory or necrotic areas, significantly improves the imaging contrast at the tumor invasion front, and provides a highly sensitive and deeply penetrating visual navigation method for precise surgical resection of tumors.

This invention discloses a method for constructing a mouse model of spontaneous brain tumor recurrence. The method includes: injecting a viral vector with a nucleotide sequence as shown in SEQ ID NO:1 into the mouse brain; after tumor formation, injecting AP20187; monitoring the in situ recurrence of residual cells within 14-21 days to obtain a mouse model of spontaneous brain tumor recurrence. This model is the first to simulate the entire process of glioblastoma development, including spontaneous tumor formation, simulated surgical resection, and highly invasive recurrence, with a 100% recurrence rate, providing an irreplaceable preclinical platform for screening anti-recurrence drugs.

The present invention is directed to methods for detecting a melanoma, methods for determining whether a melanoma is stable or progressive, methods for evaluating the extent of surgery resection in a subject having a melanoma, and methods for determining a response by a subject having a melanoma to a therapy.

The application discloses an individual structure brain network-based epilepsy postoperative curative effect prediction system and belongs to the technical field of biomedical image pattern recognition. The system is based on preoperative structural magnetic resonance imaging data of healthy subjects and epilepsy patients. Firstly, a standard structural covariant network model is constructed in the healthy subject group. Then, the preoperative structural data of the patients is added to the standard model one by one to construct an epilepsy individual disturbance offset network, and the network is standardized. Meanwhile, by adding virtual surgical resection information, the structural network characteristics of the reserved brain area after surgery are calculated and input into a support vector machine classification framework to establish a classification model related to the surgical curative effect. The system quantifies the individual structural image characteristics of the epilepsy patients by constructing the structural covariant network, and realizes intelligent prediction of the curative effect of epilepsy surgery by using the characteristics of the network, so that more comprehensive brain image information reference can be provided for preoperative accurate evaluation.

Malignant glioma has a poor prognosis, despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant cycles of TMZ. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme which removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation is a known predictor of temozolomide responsiveness; patients with unmethylated MGMT have a poorer prognosis. We employed deactivated Cas9-CRISPR technology to effectively target methylation in the vicinity of the MGMT methylation-specific polymerase chain reaction (MSP) region, as mediated by the catalytic domain of DNA methyltransferase DNMT3A. In doing so, we discovered that the selected dCas9 / CRISPR-mediated methylation of certain regions of MGMT gene sequences can be used to enhance chemosensitivity in malignant glioma cells.